Mode of action of β-cyclodextrin as an absorption enhancer of the water-soluble drug meglumine antimoniate

International Journal of Pharmaceutics

Volumn 325, Issue 1-2, 2006, Pages 39-47

  Martins, Patrícia S ^a   Ochoa, Rosemary ^a   Pimenta, Adriano M C ^a   Ferreira, Lucas A M ^a   Melo, Alan L ^a   da Silva, José B B ^a   Sinisterra, Rubén D ^a   Demicheli, Cynthia ^a   Frézard, Frédéric ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Antimony; Cyclodextrin; ESI MS; Meglumine antimoniate; Oral; Topical

Indexed keywords

BETA CYCLODEXTRIN; MEGLUMINE ANTIMONATE; PENETRATION ENHANCING AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISSOCIATION; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG SOLUBILITY; DRUG STABILITY; FEMALE; IN VITRO STUDY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; ROOM TEMPERATURE;

ADMINISTRATION, ORAL; ANIMALS; BETA-CYCLODEXTRINS; BIOLOGICAL AVAILABILITY; CIRCULAR DICHROISM; DRUG STABILITY; FEMALE; LIPID BILAYERS; MEGLUMINE; MICE; MOLECULAR WEIGHT; ORGANOMETALLIC COMPOUNDS; PERMEABILITY; SKIN; SKIN ABSORPTION; SOLUBILITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TEMPERATURE; WATER;

EID: 33750265012     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.06.014     Document Type: Article

References (19)

1. Alkhawajah A.M., Larbi E., Al-Gindan Y., Abahussein A., and Jain S. Treatment of cutaneous leishmaniasis with antimony: intramuscular versus intralesional administration. Ann. Trop. Med. Parasitol. 91 (1997) 899-905
2. Berman J.D. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin. Infect. Dis. 24 (1997) 684-703
3. Borst P., and Ouellette M. New mechanisms of drug resistance in parasitic protozoa. Annu. Rev. Microbiol. 49 (1995) 427-460
4. Brochu C., Wang J., Roy G., Messier N., Wang X.Y., Saravia N.G., and Ouellette M. Antimony uptake systems in the protozoan parasite Leishmania and accumulation differences in antimony-resistant parasites. Antimicrob. Agents Chemother. 47 (2003) 3073-3079
5. Demicheli C., Figueiredo T.L., Carvalho S., Sinisterra R.D., Lopes J.C., and Frézard F. Physico-chemical characterization of meglumine antimoniate. Biometals 12 (1999) 63-66
6. Demicheli C., Ochoa R., Lula I.S., Gozzo F.C., Eberlin M., and Frézard F. Pentavalent organoantimonial derivatives: two simple and efficient synthetic methods for meglumine antimonate. Appl. Organomet. Chem. 17 (2003) 226-231
7. Demicheli C., Ochoa R., da Silva J.B.B., de Melo A.L., Falcão C.A.M., Rossi-Bergmann B., Sinisterra R.D., and Frézard F. Oral delivery of meglumine antimoniate-beta-cyclodextrin complex for treatment of leishmaniasis. Antimicrob. Agents Chemother. 48 (2004) 100-103
8. Demicheli C., and Frézard F. Pentavalent antimonials: from chemistry to the design of new drugs. Drug Des. Rev. (online) 2 (2005) 243-249
9. Dzamitika S.A., Falcão C.A.B., Oliveira F.B., Marbeuf C., Garnier-Suillerot A., Demicheli C., Rossi-Bergmann B., and Frézard F. Role of residual Sb(III) in meglumine antimoniate cytotoxicity and MRP1-mediated resistance. Chem. Biol. Int. 160 (2006) 217-224
10. Ferreira, C.S., Pimenta, A.M.C., Demicheli, C., Frézard, F., 2006. Characterization of reactions of antimoniate and meglumine antimoniate with a guanine ribonucleoside at different pH. Biometals, in press.
11. Hirayama F., and Uekama K. Cyclodextrin-based controlled drug release system. Adv. Drug Deliv. Rev. 36 (1999) 125-141
12. Liu Z., Carbrey J.M., Agre P., and Rosen B.P. Arsenic trioxide uptake by human and rat aquaglyceroporins. Biochem. Biophys. Res. Commun. 316 (2004) 1178-1185
13. Loftsson T., and Masson M. Cyclodextrin in topical drug formulations: theory and practice. Int. J. Pharm. 225 (2001) 15-30
14. Matsuda H., and Arima H. Cyclodextrins in transdermal and rectal delivery. Adv. Drug Deliv. Rev. 36 (1999) 81-99
15. Rajewski R.A., and Stella V. Pharmaceutical applications of cyclodextrins 2. In vivo drug delivery. J. Pharm. Sci. 85 (1996) 1142-1169
16. Roberts W.L., McMurray W.J., and Rainey P.M. Characterization of the antimonial antileishmanial agent meglumine antimonate (glucantime). Antimicrob. Agents Chemother. 42 (1998) 1076-1082
17. Szejtli J. Introduction and general overview of cyclodextrin chemistry. Chem. Rev. 98 (1998) 1743-1754
18. Vernhet L., Courtois A., Allain N., Payen L., Anger J.P., Guillouzo A., and Fardel O. Overexpression of the multidrug resistance-associated protein (MRP1) in human heavy metal-selected tumor cells. FEBS Lett. 443 (1999) 321-325
19. Yan S., Jin L., and Sun H. Antimony in medicine. In: Gielen M., and Tiekink E.R. (Eds). Metallotherapeutic Drugs and Metal-Based Diagnostic Agents: The Use of Metals in Medicine vol. 10 (2005), John Wiley and Sons 441-461